BIOPHARMA
By
Can Roche’s $700M Genentech Facility Drive Its $50B US Investment Strategy and Transform Obesity Drug Manufacturing?
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Can Novartis and BioArctic’s $802M Alliance Unlock the Next Breakthrough in Neurodegenerative Drug Delivery?
Key Highlights Strategic Collaboration Targets Neurodegenerative DiseasesNovartis has entered into a research partnership with Sweden’s BioArctic, committing $30M…
Can IQVIA and Flagship Pioneering’s AI-Driven Alliance Unlock the Next $60B Wave of Breakthrough Biopharma?
Key Highlights AI-Powered Acceleration in Drug DevelopmentThe collaboration positions IQVIA’s Healthcare-grade AI® and data-driven analytics at the center…
Could Halda Therapeutics and VantAI’s $1B AI Alliance Redefine the Future of Cancer Drug Discovery?
Key Highlights Strategic Alliance to Advance Induced Proximity TherapiesHalda Therapeutics has entered into a collaboration with AI biotech…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL Amyloidosis?
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
